<trials xmlns=""><trial><main><trial_id>ISRCTN74790966</trial_id><utrn/><reg_name>ISRCTN</reg_name><date_registration>08/05/2026</date_registration><primary_sponsor>Oxford Health NHS Foundation Trust</primary_sponsor><public_title>Comparison of focused cognitive behavioural therapy and  treatment as usual in the treatment of obsessive compulsive disorder</public_title><acronym/><scientific_title>Randomised parallel trial comparing the efficacy of focused cognitive behavioural therapy versus treatment as usual for obsessive compulsive disorder</scientific_title><date_enrolment>01/06/2026</date_enrolment><type_enrolment>Anticipated</type_enrolment><target_size>68</target_size><recruitment_status>Recruiting</recruitment_status><url>https://www.isrctn.com/ISRCTN74790966</url><study_type>Interventional</study_type><study_design>Allocation: Randomized controlled trial; Masking: Open (masking not used); Control: Active; Assignment: Parallel; Purpose: Treatment;</study_design><phase>Not Applicable</phase><hc_freetext>Patients with a primary problem descriptor of obsessive compulsive disorder as identified at triage and confirmed at first assessment with therapist.</hc_freetext><i_freetext>The present randomised control trial aims to compare the efficacy of focused CBT with treatment as usual for OCD at two NHS Talking Therapy services . Focused CBT draws on the methodology outlined by Clark et al. (1999), Aslam et al. (2025), and Johnsen et al. (2025). Focused CBT sessions are supported by workbook modules, with treatment involving the development of a shared understanding of patients' OCD difficulties and the introduction of cognitive and behavioural strategies aimed at addressing factors maintaining OCD symptoms. Treatment will involve six to eight 30-minute sessions delivered online or face-to-face by psychological wellbeing practitioners. 

Treatment as usual at the services includes Guided Self-Help (GSH) and/or computerised CBT (cCBT). Interventions at both services can be delivered via phone, face-to-face, or MS Teams, depending on the individual’s preference. Both GSH and cCBT are classified as low- intensity, Step Two interventions. GSH involves a treatment planning session lasting up to 45 minutes, followed by six to eight 30-minute sessions with a PWP. Self-help materials are provided between sessions, with treatment focusing on psychoeducation and cognitive and behavioural skills. Meanwhile, cCBT is an online intervention delivered via the ‘SilverCloud’ platform. An initial ‘set-up’ call, lasting up to 20 minutes, is offered to explain the OCD programme. Patients then access the programme online, working through modules independently. Throughout the programme, patients are offered up to six online reviews, lasting up to 15 minutes each. 

Patients will be randomly allocated (using sampling without replacement) to either the intervention (focused CBT) or TAU (cCBT or GSH) condition on a 1:1 ratio in blocks of four using an online system called ‘Sealed Envelope’. A central randomisation system will be used to ensure allocation concealment, with an independent member of the research team not involved in the consent process, assigning participants to their treatment conditions. Clinical teams will be informed of the participant’s intervention condition, with services assigning therapists randomised to the condition. It will not be possible to blind therapists or participants to the intervention.</i_freetext><results_actual_enrolment>0</results_actual_enrolment><results_date_completed>27/09/2027</results_date_completed><results_url_link/><results_summary/><results_date_posted/><results_date_first_publication/><results_baseline_char/><results_participant_flow/><results_adverse_events/><results_outcome_measures/><results_url_protocol/><results_IPD_plan>No</results_IPD_plan><results_IPD_description>Not expected to be made available. </results_IPD_description></main><contacts><contact><type>Public</type><firstname>Saarim</firstname><middlename/><lastname>Aslam</lastname><address>Isis Education Centre, Warneford Hospital, Headington</address><city>Oxford</city><country1>United Kingdom</country1><zip>OX3 7JX</zip><telephone>+44 (0)7919819678</telephone><email>saarim.aslam@oxfordhealth.nhs.uk</email><affiliation/></contact><contact><type>Scientific</type><firstname>Saarim</firstname><middlename/><lastname>Aslam</lastname><address>Isis Education Centre, Warneford Hospital, Headington</address><city>Oxford</city><country1>United Kingdom</country1><zip>OX3 7JX</zip><telephone>+44 (0)7919819678</telephone><email>saarim.aslam@oxfordhealth.nhs.uk</email><affiliation/></contact><contact><type>Scientific</type><firstname>Paul</firstname><middlename/><lastname>Salkovskis</lastname><address>Isis Education Centre, Warneford Hospital, Headington</address><city>Oxford</city><country1>United Kingdom</country1><zip>OX3 7JX</zip><telephone>+44 (0)1865226369</telephone><email>paul.salkovskis@hmc.ox.ac.uk</email><affiliation/></contact></contacts><countries><country2>United Kingdom</country2><country2>England</country2></countries><criteria><inclusion_criteria>1. Aged 18+
2. Any gender
3. Problem descriptor of OCD both at triage and confirmed at first assessment with their therapist
4. Clinical level OCD symptoms on OCI total and/or subscales
5. Sufficient understanding of English to complete questionnaires and workbooks</inclusion_criteria><agemin>18 Years</agemin><agemax>120 Years</agemax><gender>All</gender><exclusion_criteria>Pre-enrolment exclusion criteria as set by services will be the following:
1. Lack of capacity to consent
2. Alcohol or substance misuse that would impact therapy and which the individual is unwilling to reduce

Trial exclusion criteria will be:
1. Acute suicide or safeguarding risk that cannot be managed
2. Current enrolment in another research study
3. Introduction or altered dose of antidepressant or anti-anxiety medication within the past month
4. Presence of a long-term health condition as their main problem
5. Inability to access study materials (e.g. no access to the internet)</exclusion_criteria></criteria><health_condition_code><hc_code/></health_condition_code><health_condition_keyword><hc_keyword>Mental and Behavioural Disorders</hc_keyword><hc_keyword/></health_condition_keyword><intervention_code><i_code/></intervention_code><intervention_keyword><i_keyword>Behavioural</i_keyword></intervention_keyword><primary_outcome><prim_outcome>Severity of OCD symptoms measured using the Obsessive Compulsive Inventory (OCI) at assessment and every intervention session</prim_outcome></primary_outcome><secondary_outcome><sec_outcome>Severity of depression symptoms measured using the Patient Health Questionnaire (PHQ-9) at assessment and every intervention session</sec_outcome><sec_outcome>Severity of anxiety symptoms measured using the Generalised Anxiety Disorder (GAD-7) Questionnaire at assessment and every intervention session</sec_outcome><sec_outcome>General functioning measured using the Work and Social Adjustment Scale (WSAS) at assessment and every intervention session</sec_outcome></secondary_outcome><secondary_sponsor><sponsor_name/></secondary_sponsor><secondary_ids><secondary_id><sec_id>357922</sec_id><issuing_authority>Integrated Research Application System (IRAS)</issuing_authority></secondary_id></secondary_ids><source_support><source_name>NIHR Oxford Biomedical Research Centre</source_name></source_support><ethics_reviews><ethics_review><status>Approved</status><approval_date>24/04/2026</approval_date><contact_name>London - Riverside Research Ethics Committee; ref: 26/LO/0107</contact_name><contact_address>2 Redman Place, Stratford, London, E20 1JQ, United Kingdom</contact_address><contact_phone>+44 020 7104 8150</contact_phone><contact_email>riverside.rec@hra.nhs.uk</contact_email></ethics_review></ethics_reviews></trial></trials>